The role of oncogenes in gastrointestinal cancer.
暂无分享,去创建一个
[1] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[2] Hansjuerg Alder,et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. , 2009, Cancer cell.
[3] L. Mazzucchelli,et al. Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.
[4] A. D. Van den Abbeele,et al. Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure , 2009, Clinical Cancer Research.
[5] C. Croce,et al. MicroRNAs in Cancer. , 2009, Annual review of medicine.
[6] Shuji Ogino,et al. A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases , 2009, Clinical Cancer Research.
[7] M. Somerfield,et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Seta Shahin,et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Bokemeyer,et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Liping Ying. A Randomized Phase IIIB Trial of Chemotherapy,Bevacizumab,and Panitumumab Compared with Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer , 2009 .
[11] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] K. Owzar,et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Ogino,et al. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype , 2008, Histopathology.
[14] H. Brenner,et al. Stool testing for the early detection of pancreatic cancer: rationale and current evidence , 2008, Expert review of molecular diagnostics.
[15] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[16] P. Assumpção,et al. MYC and gastric adenocarcinoma carcinogenesis. , 2008, World journal of gastroenterology.
[17] D. Sargent,et al. Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia , 2008, Annals of Internal Medicine.
[18] Shuji Ogino,et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.
[19] K. Hunt,et al. Genetic aberrations of gastrointestinal stromal tumors , 2008, Cancer.
[20] X. Shu,et al. Effect of Helicobacter pylori eradication on oncogenes and cell proliferation , 2008, European journal of clinical investigation.
[21] L. Neckers,et al. KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. , 2008, Leukemia research.
[22] H. Allgayer,et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer , 2008, Oncogene.
[23] C. Antonescu,et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases , 2008, Modern Pathology.
[24] S A Forbes,et al. The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.
[25] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Koopman,et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] A. Joe,et al. Oncogene addiction. , 2008, Cancer research.
[28] P. Jares,et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program , 2008, Virchows Archiv.
[29] Sreenath V. Sharma,et al. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.
[30] Safdar Ali,et al. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). , 2007, Gene.
[31] Jun Kato,et al. Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features , 2007, British Journal of Cancer.
[32] K. Ghoshal,et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.
[33] Suzanne Schubbert,et al. Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.
[34] R. Gurski,et al. c-Myc overexpression is strongly associated with metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. , 2007, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[35] M. Imoto,et al. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression , 2007, Cancer science.
[36] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[37] K. M. Woods Ignatoski,et al. Why should we still care about oncogenes? , 2007, Molecular Cancer Therapeutics.
[38] Reuven Agami,et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. , 2007, The EMBO journal.
[39] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[40] M. Sarbia,et al. c-myc amplification is frequent in esophageal adenocarcinoma and correlated with the upregulation of VEGF-A expression. , 2006, Neoplasia.
[41] Kathryn A. O’Donnell,et al. The c-Myc target gene network. , 2006, Seminars in cancer biology.
[42] A. Joe,et al. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.
[43] Wei-Yu Tang,et al. Gene-expression profiles in gastric epithelial cells stimulated with spiral and coccoid Helicobacter pylori. , 2006, Journal of medical microbiology.
[44] R. Langer,et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study , 2006, Journal of Clinical Pathology.
[45] Sarah Edkins,et al. Recurrent KRAS codon 146 mutations in human colorectal cancer , 2006, Cancer biology & therapy.
[46] A. Godwin,et al. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. , 2006, Cancer research.
[47] J. Lasota,et al. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). , 2006, Seminars in diagnostic pathology.
[48] J. Blay,et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.
[49] N. Iizuka,et al. Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus , 2006, Journal of Cancer Research and Clinical Oncology.
[50] L. Sobin,et al. Gastrointestinal Stromal Tumors of the Jejunum and Ileum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 906 Cases Before Imatinib With Long-term Follow-up , 2006, The American journal of surgical pathology.
[51] A. Ristimäki,et al. Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers , 2006, Modern Pathology.
[52] A. Jimeno,et al. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer , 2006, Molecular Cancer Therapeutics.
[53] W. Willett,et al. Cyclin D1 A870G polymorphism and the risk of colorectal cancer and adenoma , 2006, British Journal of Cancer.
[54] R. Shiekhattar,et al. MicroRNA biogenesis: isolation and characterization of the microprocessor complex. , 2006, Methods in molecular biology.
[55] S. Moss,et al. Altered expression of Skp2, c-Myc and p27 proteins but not mRNA after H. pylori eradication in chronic gastritis , 2006, Modern Pathology.
[56] Chung-Ping Hsu,et al. Clinical significance of telomerase and its associate genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus. , 2005, World journal of gastroenterology.
[57] A. Rustgi,et al. Mutant KRAS in the initiation of pancreatic cancer. , 2005, Biochimica et biophysica acta.
[58] G. Pasz-Walczak,et al. Cyclin D1 protein and CCND1 gene expression in colorectal cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[59] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Markku Miettinen,et al. KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation , 2005, Applied immunohistochemistry & molecular morphology : AIMM.
[61] M. van Glabbeke,et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] S. Evans,et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma , 2005, Cancer.
[63] M. Heinrich,et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] A. Jubb,et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. , 2005, Journal of the National Cancer Institute.
[65] G. Sauter,et al. Patterns of gene amplification in gastrointestinal stromal tumors (GIST) , 2005, Laboratory Investigation.
[66] S. Kondo,et al. Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma. , 2005, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[67] Jing-Yuan Fang,et al. The MAPK signalling pathways and colorectal cancer. , 2005, The Lancet. Oncology.
[68] P. Marynen,et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.
[69] K. Araki,et al. STI571 (Glivec) inhibits the interaction between c‐KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST‐T1 , 2005, Cancer science.
[70] J. Kononen,et al. Prevalence of KIT expression in human tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] I. Ng,et al. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. , 2004, Human pathology.
[72] M. Feitelson. c-myc overexpression in hepatocarcinogenesis. , 2004, Human pathology.
[73] Geng-yin Zhou,et al. Alteration of cyclin D1 in gastric carcinoma and its clinicopathologic significance. , 2004, World journal of gastroenterology.
[74] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[75] A. Bahnassy,et al. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients , 2004, BMC gastroenterology.
[76] V. Ambros. The functions of animal microRNAs , 2004, Nature.
[77] Lin He,et al. MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.
[78] K. Kinzler,et al. Cancer genes and the pathways they control , 2004, Nature Medicine.
[79] K. Wilson,et al. Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[80] R. Brand,et al. Reproducibility of a Multitarget Stool-Based DNA Assay for Colorectal Cancer Detection , 2004, American Journal of Gastroenterology.
[81] P. Radice,et al. Different Genetic Features Associated with Colon and Rectal Carcinogenesis , 2004, Clinical Cancer Research.
[82] J. Cigudosa,et al. Molecular alterations associated with cyclin d1 overexpression in endometrial cancer , 2004, International journal of cancer.
[83] F. Herrmann,et al. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression , 2004, Cancer.
[84] L. Rydén,et al. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients , 2004, British Journal of Cancer.
[85] Masahiro Ito,et al. Cyclin D1 overexpression in thyroid tumours from a radio‐contaminated area and its correlation with Pin1 and aberrant β‐catenin expression , 2004, The Journal of pathology.
[86] J. Fletcher. Role of KIT and platelet-derived growth factor receptors as oncoproteins. , 2004, Seminars in oncology.
[87] M. van Glabbeke,et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. , 2004, European journal of cancer.
[88] Huan-Xing Yang,et al. Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study. , 2004, World journal of gastroenterology.
[89] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[90] M. Seto,et al. Cyclin D1 Expression Is Useful as a Prognostic Indicator for Advanced Esophageal Carcinomas, but Not for Superficial Tumors , 2000, Digestive Diseases and Sciences.
[91] Gui-FangYang,et al. Expression of nuclear factor-kappa B and target genes in gastric precancerous lesions and adenocarcinoma: Association with Helicobactor pylori cagA (+) infection , 2004 .
[92] Chenguang Wang,et al. Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential. , 2004, Cancer treatment and research.
[93] L. Le Marchand,et al. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. , 2003, JAMA.
[94] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] R. Schneider-Stock,et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. , 2003, Human pathology.
[96] H. Bidd,et al. Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. , 2003, Human pathology.
[97] Andrew J. Wilson,et al. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis , 2003, British Journal of Cancer.
[98] D. Beer,et al. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[99] E. Wardelmann,et al. Deletion of Trp‐557 and Lys‐558 in the juxtamembrane domain of the c‐kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors , 2003, International journal of cancer.
[100] R. Hruban,et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. , 2003, The American journal of pathology.
[101] Andrea Tannapfel,et al. Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays , 2003, The Journal of pathology.
[102] S. Hirota,et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.
[103] D. Amadori,et al. Fecal multiple molecular tests to detect colorectal cancer in stool. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[104] M. Ladanyi,et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[105] G. Kuang,et al. Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population , 2003, International journal of cancer.
[106] M. Lawson,et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. , 2003, Clinical colorectal cancer.
[107] Avijit Chakrabartty,et al. Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region , 2003, Molecular and Cellular Biology.
[108] Andrea Cocito,et al. Genomic targets of the human c-Myc protein. , 2003, Genes & development.
[109] B. Iacopetta,et al. Prognostic Significance of Microsatellite Instability and Ki-ras Mutation Type in Stage II Colorectal Cancer , 2003, Oncology.
[110] R. Goldbohm,et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. , 2003, Carcinogenesis.
[111] B. Klump,et al. C-myc gene amplification in different stages of oesophageal squamous cell carcinoma: prognostic value in relation to treatment modality. , 2003, Anticancer research.
[112] B. C. Wong,et al. Effect of Helicobacter pylori on apoptosis and apoptosis related genes in gastric cancer cells , 2003, Molecular pathology : MP.
[113] D. Wakelin,et al. Upregulation of the oncogene c-myc in Barrett’s adenocarcinoma: induction of c-myc by acidified bile acid in vitro , 2003, Gut.
[114] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[115] X. Guan,et al. Prognostic significance of c‐myc and AIB1 amplification in hepatocellular carcinoma , 2002, Cancer.
[116] Tony Pawson,et al. Regulation and targets of receptor tyrosine kinases. , 2002, European journal of cancer.
[117] T. Aoki,et al. Cell cycle-regulated factors in esophageal cancer. , 2002, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[118] G. Demetri. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). , 2002, European journal of cancer.
[119] K. Kinzler,et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.
[120] I. Weinstein. Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.
[121] O. Delpuech,et al. Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma , 2002, Oncogene.
[122] Y. Nakagawa,et al. A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/restriction fragment length polymorphism analysis. , 2002, Clinica chimica acta; international journal of clinical chemistry.
[123] E. Wardelmann,et al. c-kit Mutations in Gastrointestinal Stromal Tumors Occur Preferentially in the Spindle Rather Than in the Epithelioid Cell Variant , 2002, Modern Pathology.
[124] J. Shimazaki,et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[125] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[126] T. Takayama,et al. Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. , 2001, Gastroenterology.
[127] 이석호,et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.
[128] Y. Shyr,et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. , 2001, Cancer research.
[129] A. Pasquinelli,et al. A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the let-7 Small Temporal RNA , 2001, Science.
[130] A. Xu,et al. Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer. , 2001, World journal of gastroenterology.
[131] P. Catalano,et al. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. , 2001, Cancer research.
[132] M. Wolter,et al. Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett esophagus. , 2001, American journal of clinical pathology.
[133] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[134] T. Nishida,et al. Gain‐of‐function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours , 2001, The Journal of pathology.
[135] T. Tsunoda,et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. , 2001, Cancer research.
[136] J. Aster,et al. Molecular biology of Burkitt's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[137] S. Thibodeau,et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. , 2000, Gastroenterology.
[138] M. Leppert,et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[139] J. McKay,et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer , 2000, International journal of cancer.
[140] D. Forman,et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. , 2000, Journal of the National Cancer Institute.
[141] I. Weinstein. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. , 2000, Carcinogenesis.
[142] E. de Álava,et al. Predicting Metastatic Risk of Gastrointestinal Stromal Tumors: Role of Cell Proliferation and Cell Cycle Regulatory Proteins , 2000, International journal of surgical pathology.
[143] S. Hammond,et al. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells , 2000, Nature.
[144] K. Klempnauer,et al. Regulation of B-Myb activity by cyclin D1 , 2000, Oncogene.
[145] R Mera,et al. Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. , 2000, Human pathology.
[146] G. Capellá,et al. A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. , 2000, International journal of cancer.
[147] R. DeMatteo,et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.
[148] Y. Takano,et al. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis , 1999, The Journal of pathology.
[149] G. Hommel,et al. Expression of cell‐cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer , 1999, The Journal of pathology.
[150] M. Wolter,et al. Expression of Bcl-2 and amplification of c-myc are frequent in basaloid squamous cell carcinomas of the esophagus. , 1999, The American journal of pathology.
[151] M. S. Lee,et al. c-Myc expression is related with cell proliferation and associated with poor clinical outcome in human gastric cancer. , 1999, Journal of Korean medical science.
[152] Y. Morishita,et al. Amplification of c-myc in Hepatocellular Carcinoma: Correlation with Clinicopathologic Features, Proliferative Activity and p53 Overexpression , 1999, Oncology.
[153] D. Felsher,et al. Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.
[154] M. Schwab. Oncogene amplification in solid tumors. , 1999, Seminars in cancer biology.
[155] J. Segall,et al. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. , 1999, Endocrine reviews.
[156] M. Monden,et al. Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence , 1999, Hepatology.
[157] S. Goodman,et al. Genetic epidemiology of mutated K-rasproto-oncogene, altered suppressor genes, and microsatellite instability in colorectal adenomas , 1999, Gut.
[158] E. Prochownik,et al. MYC oncogenes and human neoplastic disease , 1999, Oncogene.
[159] L. Regan,et al. Inhibition of Spontaneous Receptor Phosphorylation by Residues in a Putative α-Helix in the KIT Intracellular Juxtamembrane Region* , 1999, The Journal of Biological Chemistry.
[160] Q. Wei,et al. Coupling of the cell cycle and myogenesis through the cyclin D1‐dependent interaction of MyoD with cdk4 , 1999, The EMBO journal.
[161] A. Sparks,et al. Identification of c-MYC as a target of the APC pathway. , 1998, Science.
[162] H. Hsu,et al. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. , 1998, Journal of hepatology.
[163] M. Schwab. Amplification of oncogenes in human cancer cells , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[164] A. Norman,et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.
[165] S. Kitano,et al. Prognostic significance of c-myc mRNA expression assessed by semi-quantitative RT-PCR in patients with colorectal cancer. , 1998, Oncology reports.
[166] C. Sherr,et al. Gene Expression and Cell Cycle Arrest Mediated by Transcription Factor DMP1 Is Antagonized by D-Type Cyclins through a Cyclin-Dependent-Kinase-Independent Mechanism , 1998, Molecular and Cellular Biology.
[167] D. Schiffer,et al. Cyclin D1 expression in gliomas , 1998, Acta Neuropathologica.
[168] K. Maeda,et al. Cyclin D1 Overexpression and Prognosis in Colorectal Adenocarcinoma , 1998, Oncology.
[169] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[170] M. Imamura,et al. Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. , 1997, Annals of surgery.
[171] P. Chikhlikar,et al. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma , 1997, Diseases of the colon and rectum.
[172] K. Maeda,et al. Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma , 1997, International journal of cancer.
[173] G. Corner,et al. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. , 1997, Cancer research.
[174] R. Herrmann,et al. Overexpression and amplification of c-myc during progression of human colorectal cancer. , 1996, Oncology.
[175] M. Kitajima,et al. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[176] Y. Kohata. [Detection of K-ras point mutations in the stool of patients with colorectal tumors]. , 1996, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.
[177] A. Neugut,et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[178] C. Wagener,et al. Detection of K‐ras mutations in stools of patients with colorectal cancer by mutant‐enriched PCR , 1996, International journal of cancer.
[179] A. Rebecchi,et al. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. , 1996, Gastroenterology.
[180] T. Kanematsu,et al. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer , 1996, Cancer.
[181] H. Hibshoosh,et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. , 1996, Gastroenterology.
[182] T. Gansler,et al. c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[183] G. Peters,et al. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. , 1996, Advances in cancer research.
[184] Y. Chung,et al. Overexpression of c-myc messenger RNA in primary and metastatic lesions of carcinoma of the stomach. , 1996, Journal of the American College of Surgeons.
[185] M. Ogawa,et al. Ethnic difference in the pattern of K‐ras oncogene mutations in human colorectal cancers , 1996, Human mutation.
[186] N Thatcher,et al. Alternate splicing produces a novel cyclin D1 transcript. , 1995, Oncogene.
[187] R. Weinberg,et al. The retinoblastoma protein and cell cycle control , 1995, Cell.
[188] T. Hattori,et al. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. , 1995, The American journal of pathology.
[189] H. Ohta,et al. Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). , 1995, Oncogene.
[190] H. Esumi,et al. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. , 1995, Gastroenterology.
[191] M. Eisenstein,et al. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction , 1995, Cell.
[192] W. Bodmer,et al. Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. , 1995, Gut.
[193] D. Klimstra,et al. K-ras mutations in pancreatic ductal proliferative lesions. , 1994, The American journal of pathology.
[194] C. Sherr. G1 phase progression: Cycling on cue , 1994, Cell.
[195] J. Bartek,et al. The PRAD‐1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas , 1994, International journal of cancer.
[196] R. Hruban,et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. , 1994, Cancer research.
[197] N. Nishida,et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. , 1994, Cancer research.
[198] T. Saito,et al. c-myc mRNA overexpression is associated with lymph node metastasis in colorectal cancer. , 1994, European journal of cancer.
[199] V. Ambros,et al. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.
[200] H. Kim,et al. Expression of cellular oncogenes in human gastric carcinoma: c‐myc, c–erb B2′ and c‐Ha‐ras , 1993, Journal of surgical oncology.
[201] C. J. Chen,et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. , 1993, Biochemical and biophysical research communications.
[202] C. Harris,et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[203] H. Hsu,et al. Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. , 1993, Journal of the Formosan Medical Association = Taiwan yi zhi.
[204] S. Goodman,et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. , 1993, The American journal of pathology.
[205] S. Lev,et al. Structure‐function analyses of the kit receptor for the steel factor , 1993, Stem cells.
[206] H. Saisho,et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. , 1993, Cancer research.
[207] P. Quirke,et al. p53 expression and K-ras mutation in colorectal adenomas. , 1993, Gut.
[208] S. Nishikawa,et al. Interspecies molecular chimeras of kit help define the binding site of the stem cell factor , 1993, Molecular and cellular biology.
[209] K. Stȩpniewska,et al. High frequency of K-ras mutations in sporadic colorectal adenomas. , 1993, Gut.
[210] M. Brizzi,et al. Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor. , 1993, The Journal of biological chemistry.
[211] Bruno Amati,et al. Oncogenic activity of the c-Myc protein requires dimerization with Max , 1993, Cell.
[212] R. Eisenman,et al. Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity , 1993, Cell.
[213] I. Weinstein,et al. Amplification and expression of the human cyclin D gene in esophageal cancer. , 1992, Cancer research.
[214] G. Fourel,et al. Frequent amplification of c-myc in ground squirrel liver tumors associated with past or ongoing infection with a hepadnavirus. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[215] R. Eisenman,et al. Myc and Max function as a nucleoprotein complex , 1992, Current Biology.
[216] K. Kinzler,et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. , 1992, Science.
[217] L. Pavelic,et al. High c-myc protein expression in benign colorectal lesions correlates with the degree of dysplasia. , 1992, Anticancer research.
[218] N. Harris,et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[219] A. Arnold,et al. A novel cyclin encoded by a bcl1-linked candidate oncogene , 1991, Nature.
[220] J. Bishop. Molecular themes in oncogenesis , 1991, Cell.
[221] Frank McCormick,et al. The GTPase superfamily: conserved structure and molecular mechanism , 1991, Nature.
[222] L. Augenlicht,et al. Aggressive subtypes of human colorectal tumors frequently exhibit amplification of the c-myc gene. , 1991, Oncogene.
[223] H. Shiku,et al. Expression of c-myc gene product in gastric carcinoma. , 1991, Oncology.
[224] R. Eisenman,et al. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.
[225] M. Meldrum,et al. Nobel Laureates in Medicine or Physiology , 1990 .
[226] A. Pardee. G1 events and regulation of cell proliferation. , 1989, Science.
[227] G. Stenman,et al. Human PDGFA receptor gene maps to the same region on chromosome 4 as the KIT oncogene , 1989, Genes, chromosomes & cancer.
[228] P. Newmark. Nobel for oncogenes , 1989, Nature.
[229] A. Look,et al. Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes , 1988, Cell.
[230] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[231] G. Fleuren,et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. , 1988, Nucleic acids research.
[232] D. Shibata,et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.
[233] S. Litwin,et al. Noncorrelation of the expression of the c-myc oncogene in colorectal carcinoma with recurrence of disease or patient survival. , 1988, Cancer Research.
[234] A. Ullrich,et al. Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.
[235] B. Wilson,et al. Abnormal distribution of c-myc oncogene product in familial adenomatous polyposis. , 1987, Journal of clinical pathology.
[236] J. Costa,et al. Prognostic implications of expression of the cellular genes myc, fos, Ha‐ras and Ki‐ras in colon carcinoma , 1987, International journal of cancer.
[237] K. Sikora,et al. c‐myc oncogene expression in colorectal cancer , 1987, Cancer.
[238] F. Alt,et al. Myc family of cellular oncogenes , 1987, Journal of cellular biochemistry.
[239] William E. Grizzle,et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis , 1987, Nature.
[240] B. Vogelstein,et al. Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.
[241] John E. Murphy,et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.
[242] J. Yokota,et al. Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. , 1986, Science.
[243] J. Stewart,et al. Detection of the c-myc oncogene product in colonic polyps and carcinomas. , 1986, British Journal of Cancer.
[244] M. Erisman,et al. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene , 1985, Molecular and cellular biology.
[245] R. Weinberg,et al. Cellular oncogenes and multistep carcinogenesis. , 1983, Science.
[246] P. Leder,et al. The human c-myc oncogene: Structural consequences of translocation into the igh locus in Burkitt lymphoma , 1983, Cell.
[247] P. Rothberg,et al. Oncogenes and cancer. , 1983, Cancer investigation.
[248] C. Croce,et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[249] R. Weinberg,et al. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene , 1982, Nature.
[250] B. Vennstrom,et al. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29 , 1982, Journal of virology.
[251] J. Bishop. Retroviruses and cancer genes. , 1982, Advances in cancer research.
[252] J. Bishop,et al. Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29 , 1978, Journal of virology.
[253] H. Varmus,et al. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA , 1976, Nature.
[254] P. Vogt,et al. Differences between the Ribonucleic Acids of Transforming and Nontransforming Avian Tumor Viruses* , 1970, Proceedings of the National Academy of Sciences.
[255] H. Temin,et al. Characteristics of an assay for Rous sarcoma virus and Rous sarcoma cells in tissue culture. , 1958, Virology.
[256] P. Rous. A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS , 1911, The Journal of experimental medicine.
[257] P. Rous,et al. A TRANSMISSIBLE AVIAN NEOPLASM. (SARCOMA OF THE COMMON FOWL.) , 1910, The Journal of experimental medicine.